Inflammation and Immunology
In February 2019, Evotec and Galapagos announced a global collaboration focused on a novel target for fibrosis and other indications.
The collaboration concerns a small molecule programme, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec’s proprietary platforms for fibrotic diseases and NASH. Evotec utilised its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains undisclosed.
In exchange for global commercialisation rights to Galapagos, Evotec receives an upfront payment and is eligible for potential milestone and royalty payments. Galapagos will be responsible for all further development of the programme. Furthermore, Galapagos will have access to specific screening formats at Evotec to support the final pre-clinical development.
In September 2015 Evotec announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis.
Under the terms of this licence and collaboration agreement, scientists at Evotec and Pfizer explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec contribute its drug discovery platform whereas Pfizer provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise.
Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones.
CONBA Pharmaceutical/ EVT401
In May 2012, Evotec and CONBA Pharmaceutical Co., Ltd. announced the grant of a development and marketing licence on EVT401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease (“COPD”) and endometriosis in China.
Evotec received a small upfront payment and is eligible for development and commercial milestone payments in excess of € 60 m and tiered double-digit royalties on net sales. The agreement grants CONBA exclusive rights to develop and commercialise the compound for the Chinese market. Evotec will have the right to reference clinical data produced by CONBA Pharmaceutical to support potential further development of EVT401 in other territories.
P2X7 receptor antagonism may provide a novel approach for the treatment of inflammatory conditions. Evotec has completed the first Phase I, single dose study of EVT 401 in 2010. CONBA will initiate further clinical trials with EVT401 in China in inflammatory diseases. In July 2013, CONBA received green light from the Chinese government to continue their studies on the EVT401 programme.